Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Allergic conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Eleven Biotherapeutics; Sesen Bio

Most Recent Events

  • 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
  • 29 Apr 2016 According to an Eleven Biotherapeutics media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting.
  • 10 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top